Antitubulin agents;Les agents antitubulines

Bulletin du Cancer

Volumn 98, Issue 11, 2011, Pages 1275-1285

  Dumontet, Charles ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Antitubulin agents; Epothilones; Microtubules; Taxanes; Tubulin; Vinca alkaloids

Indexed keywords

ANTIBODY CONJUGATE; ANTIMITOTIC AGENT; ANTITUBULIN AGENT; CYTOSKELETON PROTEIN; DNA; ERIBULIN; IXABEPILONE; MAYTANSINE; MICROTUBULE BINDING AGENT; MICROTUBULE PROTEIN; MONOCLONAL ANTIBODY; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCA ALKALOID;

HUMAN; MARINE SPECIES; MEDICAL LITERATURE; MICROTUBULE; NEUROTOXICITY; NONHUMAN; REVIEW; SCREENING TEST; TUMOR;

EID: 82455191623     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1469     Document Type: Review

References (34)

1. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci 1958; 76 : 882-94.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277 : 665-7. (Pubitemid 9114288)
3. Pajk B, Cufer T, Canney P, et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008; 17 : 180-5. (Pubitemid 351467955)
4. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23 : 3125-37. (Pubitemid 46224136)
5. Nicolaou KC, Yang Z, Liu JJ, et al. Total synthesis of taxol. Nature 1994; 367 : 630-4. (Pubitemid 24069071)
6. Sammak PJ, Borisy GG. Direct observation of microtubule dynamics in living cells. Nature 1988; 332 : 724-6.
7. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9 : 790-803.
8. Infante JR, Yardley DA, Burris HA, et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 2009; 9 : 23-8.
9. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5 : 423-35. (Pubitemid 40791485)
10. Tozer GM, Prise VE,Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61 : 6413-22. (Pubitemid 32785286)
11. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77 : 1761-7. (Pubitemid 28254609)
12. Kuttesch JF, Parham DM, Luo X, et al. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 1996; 14 : 886-900.
13. Lhomme C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008; 26 : 2674-82.
14. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38 : 69-74. (Pubitemid 30077981)
15. Galmarini CM, Kamath K, Vanier-Viornery A, et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88 : 1793- 9.
16. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008; 9 : 168-75. (Pubitemid 351150128)
17. Don S, Verrills NM, Liaw TY, et al. Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. Mol Cancer Ther 2004; 3 : 1137-46. (Pubitemid 39295011)
18. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2 : 72-9. (Pubitemid 26029571)
19. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006; 66 : 8731-9. (Pubitemid 44449190)
20. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27 : 4454-61.
21. Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previourly treated with an anthracycline and a taxane. J Clin Oncol 2010 ; 28 : 7S (Abstract CRA1004).
22. Besse-Hammer T, Villanueva C, Campone M, et al. A doseescalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer progressing after anthracycline and taxane therapy: Preliminary results. - ASCO. J Clin Oncol 2009; 27 (abstract 1053).
23. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27 : 3611-9.
24. Chou TC, Zhang XG, Harris CR, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998; 95 : 15798-802. (Pubitemid 29018780)
25. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21 : 2815-22. (Pubitemid 46621828)
26. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19 : 233-40.
27. D'Agostino G, del Campo J, Mellado B, et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006; 16 : 71-6.
28. Anderl JL, Redpath S, Ball AJ. A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity. J Vis Exp 2009; 27; doi:10.3791/1173.
29. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27 : 2954-61.
30. Wienecke A, Bacher G. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res 2009; 69 : 171-7.
31. Blagden SP, Molife LR, Seebaran A, et al. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 2008; 98 : 894-9. (Pubitemid 351341614)
32. Swanton C, Nicke B, Schuett M, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 2009; 106 : 8671-6.
33. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2010; 29 : 398-405.
34. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998; 42 : 127-34. (Pubitemid 28267293)